RecruitingNCT07264426

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

Sponsor

argenx

Enrollment

200 participants

Start Date

Aug 11, 2025

Study Type

OBSERVATIONAL

Conditions

Chronic Inflammatory Demyelinating Polyradiculoneuropathy CIDP CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)

Summary

The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod. As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care. Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Efgartigimod PH20 SC for people with cidp, cidp (chronic inflammatory demyelinating polyradiculoneuropathy), and other related conditions. The study is currently recruiting participants at 23 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALEfgartigimod PH20 SC

Efgartigimod treatment per country-specific label for the treatment of CIDP

Locations(23)

PPD Virtual

Wilmington, North Carolina, United States

Jüdisches Krankenhaus Berlin

Berlin, Germany

Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH

Bochum, Germany

UK-RUB - Katholisches Klinikum Bochum - St. Josef Hospital

Bochum, Germany

Universitätsklinikum Köln

Cologne, Germany

Universitätsklinikum Düsseldorf

Düsseldorf, Germany

Universitätsklinikum Frankfurt

Frankfurt, Germany

UKGM - Universitätsklinikum Gießen und Marburg GmbH

Giessen, Germany

Universitätsmedizin Göttingen

Göttingen, Germany

Universitätsklinikum Hamburg Eppendorf

Hamburg, Germany

Neurologie Neuer Wall - Dr.Bredow & Partner

Hamburg, Germany

Medizinische Hochschule Hannover

Hanover, Germany

Universitatsklinikum des Saarlandes

Homburg, Germany

Universitätsklinikum Magdeburg A.ö.R.

Magdeburg, Germany

Universitätsklinikum Mannheim

Mannheim, Germany

Universitätsklinikum Gießen und Marburg GmbH - Standort Marburg

Marburg, Germany

Mühlenkreiskliniken - Johannes Wesling Klinikum Minden

Minden, Germany

Friedrich-Baur-Institute München

München, Germany

Alexianer St. Josef Potsdam GmbH

Potsdam, Germany

Immanuel Klinik Rüdersdorf

Rüdersdorf, Germany

Diakonie-Klinikum Schwäbisch Hall gGmbH

Schwäbisch Hall, Germany

Universitätsklinikum Tübingen

Tübingen, Germany

Universitätsklinikum Ulm

Ulm, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07264426

Related Trials

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

NCT0692000482 locations

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

NCT0709163071 locations

A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT075402217 locations

Biomarkers in Autoimmune Disease of Nervous System

NCT065020151 location

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

NCT06290128131 locations